Jump to content

Genedata Selector
Open Forum Registration

Genedata Selector is committed to facilitating the exchange of knowledge and discussion of best practices of Next-Generation Sequencing (NGS) for cell and gene therapy development, biosafety testing and cell line development. To this end, Genedata Selector regularly hosts exclusive community-building industry workshops with leading biopharmaceutical companies, featuring expert presentations and discussions on key industry challenges and opportunities to learn and share perspectives.

Our most recent Open Forum with Astellas focused on product development and characterization for cell and gene therapies. With Sarepta Therapeutics, we held one event focusing on NGS-based assays for AAV vector production and characterization, multi-attribute method (MAM) approaches, and biosafety. With Bristol Myers Squibb (BMS), we held four events focusing on NGS-based biosafety testing and its benefits for biopharma R&D and regulatory practices. We also held two events with Boehringer Ingelheim, focusing on NGS-based cell line development (CLD). These events provided a platform for subject matter experts to share their experiences in cell line characterisation, multi-omics data integration and analysis.

Read About Our Meetings

Cell Line Development
Cell and Gene Therapy

Register Your Interest in Our Next Events

Attendees at previous Genedata Selector Open Forums

Disclaimer: The purpose of our meeting and discussions is to initiate a pre-competitive R&D collaboration and to discuss Next-Generation Sequencing (NGS) in gene and cell therapy, multi-attribute method (MAM) approaches, and biosafety. We consider our discussions to be pre-competitive in nature, as the best practices can be used very widely in the industry. Please keep the conversation on this topic and refrain from raising issues that could be considered anti-competitive under antitrust and competition laws, such as pricing.